		<div class="wpcnt">
			<div class="wpa">
				<span class="wpa-about">Advertisements</span>
				<div class="u top_amp">
							<amp-ad width="300" height="265"
		 type="pubmine"
		 data-siteid="111265417"
		 data-section="2">
		</amp-ad>
				</div>
			</div>
		</div><p><a href="http://londonglossy.com/wp-content/uploads/2010/12/astrazeneca-halts-work-on-lung-drug.jpg"><img class="alignnone size-full" title="AstraZeneca has halted developments on a lung treatment drug" src="http://londonglossy.com/wp-content/uploads/2010/12/min-astrazeneca-halts-work-on-lung-drug.jpg" alt="AstraZeneca has halted developments on a lung treatment drug"/></a></p>
<p>Pharmaceuticals giant AstraZeneca has revealed its second drugs blow in a week as it said it had dropped development of one of its experimental treatments.</p>
<p>The group said its motavizumab drug to prevent serious lung disease in infants had been discontinued, leading to a 445 million US dollar (£287.2 million) accounting charge.</p>
<p>The news follows AstraZeneca&#8217;s disappointment last week over a further delay in winning approval from US regulators for its heart medicine Brilinta.</p>
<p>The US Food and Drug Administration (FDA) wanted further analysis of research into Brilinta &#8211; a blood-thinning pill &#8211; before clearing the drug for sale.</p>
<p>Shares slumped as hopes are running high for the treatment, which has already been approved in Europe and is designed to rival blockbuster Plavix, the world&#8217;s second biggest selling drug.</p>
<p>But the group&#8217;s shares shrugged off the news, with AstraZeneca confirming the fourth quarter financial hit would not impact core earnings.</p>
<p>Its decision to pull development of motavizumab has not come as a surprise to analysts after the drug hit troubles with the FDA in America.</p>
<p>A US medical advisory panel cited concerns last June over potentially serious side effects, while the FDA added to delays by issuing a second so-called complete response letter this August.</p>
<p>However, AstraZeneca confirmed motavizumab remains in development for other serious respiratory syncytial virus (RSV) treatment.</p>
<p>AstraZeneca employs 11,000 staff in the UK and has sites at Macclesfield and Wilmslow in Cheshire, Luton, Loughborough, Edinburgh and Brixham in Devon.</p>
			<div style="padding-bottom:15px;" class="wordads-tag" data-slot-type="belowpost">
				<div id="atatags-dynamic-belowpost-68ed912b08c53">
					<script type="text/javascript">
						window.getAdSnippetCallback = function () {
							if ( false === ( window.isWatlV1 ?? false ) ) {
								// Use Aditude scripts.
								window.tudeMappings = window.tudeMappings || [];
								window.tudeMappings.push( {
									divId: 'atatags-dynamic-belowpost-68ed912b08c53',
									format: 'belowpost',
								} );
							}
						}

						if ( document.readyState === 'loading' ) {
							document.addEventListener( 'DOMContentLoaded', window.getAdSnippetCallback );
						} else {
							window.getAdSnippetCallback();
						}
					</script>
				</div>
			</div>
Discover more from London Glossy Post
Subscribe to get the latest posts sent to your email.
